Preventing the cardiovascular complications of hypertension

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Preventing the cardiovascular complications of hypertension"

Transcription

1 European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany KEYWORDS AT 1 -receptor blockers; Candesartan; Cardiovascular events; End-organ protection; LIFE; SCOPE; VALUE AT 1 -receptor blockers reduce blood pressure and also show other beneficial effects on target organs. Meta-analyses and studies such as the CATCH Study with candesartan show that AT 1 -receptor blockers are as effective as, or more effective than, other antihypertensive agents in reversing left-ventricular hypertrophy, while nephroprotective effects have been demonstrated in a number of clinical endpoint studies. Similarly, neuroprotective effects have been shown in laboratory and clinical studies, including the ACCESS Study with candesartan. The LIFE Study with losartan and the SCOPE Study with candesartan have investigated the impact of AT 1 -receptor blockade on cardiovascular complications in hypertension. LIFE showed that AT 1 -receptor blockade significantly reduced the risk of cardiovascular death, stroke or myocardial infarction, compared with b-blockers, while SCOPE showed a significant reduction in non-fatal stroke in candesartan-treated patients, compared with control treatment. An analysis in patients from SCOPE who did not receive open-label, add-on antihypertensive therapy after randomization showed a significant 32% reduction in major cardiovascular events with candesartan. The recently reported VALUE study found no difference in overall cardiac disease between valsartanbased and amlodipine-based therapy, but demonstrated the importance of bloodpressure control in high-risk individuals, with some cause-specific endpoints favouring amlodipine-based therapy. New-onset diabetes was less frequent with AT 1 -receptor blockade than control therapy in all of the three major intervention trials with AT 1 -receptor blockers in hypertension The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved. Introduction An ideal antihypertensive therapy should achieve three aims. First, it should normalize raised blood pressure; second, it should prevent complications of hypertension; and, third, it should achieve these aims without compromising the patient s quality of life. It is increasingly accepted that AT 1 -receptor blockers fulfil these aims: they produce dose-dependent blood-pressure reductions that are sustained for at least 24 hours (48 hours in the case of candesartan) 1 ; they show * Correspondence: Prof.Dr. Peter Trenkwalder, MD. Klinikum Starnberg, Osswaldstr. 1 D Starnberg, Germany. Tel.: ; fax: address: (P. Trenkwalder). placebo-like tolerability across their full dosing range 1, and are metabolically neutral 2 ; and evidence from an increasing number of studies shows that they have beneficial effects on target organs such as the heart, kidney and brain, and reduce mortality and morbidity in hypertensive patients 3 9. Cardioprotective effects of AT 1 -receptor blockers Hypertension and other cardiovascular risk factors are key initiating events in the cardiovascular continuum, leading to the development of atherosclerosis and coronary artery disease (CAD), and subsequently to myocardial infarction and progressive deterioration in cardiac function (Fig. 1) 10. The development of left /$ see front matter 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

2 H38 P. Trenkwalder Before After Fig. 1. The cardiovascular continuum. Adapted from Dzau and Braunwald ventricular hypertrophy (LVH) is a critical event in this continuum, since LVH is associated with a significantly increased risk of cardiovascular disease and stroke. Data from the Framingham study, for example, show that LVH increases the risk of heart failure approximately seven-fold, and those of stroke or death from CAD approximately six-fold 11. Antihypertensive therapy can produce regression of LVH, but the extent of this regression varies markedly between different classes of agents. A recent meta-analysis, incorporating data from 80 trials with a total of more than 4000 patients, showed that the greatest reductions in left-ventricular mass are achieved with AT 1 -receptor blockers (mean decrease 13%; 95% confidence interval [CI]: 8 18%), followed by calcium antagonists (11%; 95% CI: 9 13%), angiotensin-converting-enzyme (ACE) inhibitors (10%; 95% CI: 8 12%), diuretics (8%; 95% CI: 5 10%) and b-blockers (6%; 95% CI: 3 8%) 12.AT 1 -receptor blockers, ACE inhibitors and calcium antagonists were found to be significantly (P<0.05) more effective in reducing LVH than b-blockers. These differences have also been demonstrated in comparative studies. In one such study, 114 hypertensive patients (mean diastolic blood pressure mmhg) were randomized to receive candesartan 16 mg once daily, or hydrochlorothiazide 25 mg once daily, for 1 year 13. Candesartan significantly (P<0.003) reduced left-ventricular mass, compared with baseline values, whereas no significant change was seen in hydrochlorothiazide-treated patients (Fig. 2). The reduction in ventricular mass in candesartan-treated patients was associated with significant improvements in diastolic function. Both treatments maintained mean diastolic blood pressure below 90 mmhg, suggesting that the effect of candesartan on LVH was independent of changes in blood pressure. The Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) Study compared candesartan 8 16 mg and enalapril mg in 239 hypertensive patients with LVH (echocardiographic left-ventricular mass index [LVMI] >120 g/m 2 in men or >100 g/m 2 in women) 7. Treatment was continued for 48 weeks, and LVMI was measured by two-dimensionally guided M-mode echocardiography at baseline and at 24 and 48 weeks. Both candesartan and enalapril significantly (P<0.001) reduced systolic and diastolic blood pressure, 16 mg CC n=82 25 mg HCT n=32 Fig. 2. Change in left ventricular mass in 114 hypertensive patients treated with candesartan cilexetil (CC) 16 mg or hydrochlorothiazide (HCT) 25 mg, for 1 year 13.*P<0.003 vs. baseline. compared with baseline, and there was no significant difference between the blood-pressure reductions in the two groups. The proportion of patients in whom blood-pressure control (defined as blood pressure below 140/90 mmhg) was achieved was 60.4% in the candesartan group and 60.0% in the enalapril group. Both treatments produced significant reductions in LVMI, compared with baseline: the mean decrease in LVMI was 15.0±22.6(SD) g/m 2 (10.9±15.5%) with candesartan and 13.2±23.4 g/m 2 (8.4±17.4%) with enalapril. The difference between the reductions achieved with the two treatments was not statistically significant (mean 2.0 g/m 2 candesartan minus enalapril; 95% CI: 8.3 to +4.2). The proportion of patients showing regression of LVH at 24 weeks was 30% in the candesartan group, compared with 25% in the enalapril group; the corresponding figures at 48 weeks were 36% and 30%, respectively. This study shows, therefore, that AT 1 -receptor blockade with candesartan is at least as effective as ACE inhibition with enalapril in reducing blood pressure and left-ventricular mass in hypertensive patients with LVH. Nephroprotective effects of AT 1 -receptor blockers Early studies with ACE inhibitors had shown that blockade of the renin angiotensin system has nephroprotective effects in diabetic patients 14,15, raising the possibility that similar benefits might be obtained with AT 1 -receptor blockers. Preliminary evidence to support such effects came from studies using surrogate endpoints such as microalbuminuria. In one such study, 161 hypertensive patients (sitting diastolic blood pressure mmhg) with stable type-2 diabetes were treated with candesartan 8 16 mg once daily or placebo for 12 weeks 16. Candesartan treatment resulted in a significant reduction in urinary albumin excretion in patients with microalbuminuria, whereas urinary albumin excretion increased in placebo-treated patients (Fig. 3). The difference between the two treatments was statistically significant (P = 0.03). Subsequently, several large randomized clinical endpoint trials have confirmed the nephroprotective effects of AT 1 -receptor blockers, showing that these agents significantly reduce

3 Preventing the cardiovascular complications of hypertension H39 Fig. 3. Effect of treatment for 12 weeks with candesartan 8 16 mg or placebo in hypertensive patients with type-2 diabetes and microalbuminuria 16. mortality and morbidity associated with hypertensive renal disease, particularly in diabetic patients 4 6.Inthe Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study, for example, treatment with losartan was associated with significant reductions in the risk of doubling of serum creatinine and of developing end-stage renal failure 5. In the Irbesartan Diabetic Nephropathy Trial (IDNT), AT 1 -receptor blockade reduced the incidence of the primary endpoint (a composite of doubling of serum creatinine, development of end-stage renal disease, or death from any cause) by 20% compared with placebo (P = 0.02) and by 23% compared with amlodipine (P = 0.006) 4. Similarly, in the Irbesartan in patients with type-2 diabetes and Microalbuminuria (IRMA 2) Study, treatment with an AT 1 -receptor blocker resulted in a significant delay in the onset of diabetic nephropathy, compared with placebo. These nephroprotective effects were independent of changes in blood pressure. Neuroprotective effects of AT 1 -receptor blockers An increasing volume of animal and clinical data shows that AT 1 -receptor blockers may offer neuroprotective effects. In a study in stroke-prone spontaneously hypertensive rats, for example, treatment with candesartan, at doses of both 10 mg/kg (a dose producing bloodpressure reduction) and 0.1 mg/kg (which does not affect blood pressure), significantly reduced the incidence of stroke, compared with that in control animals 17. The clinical significance of such effects was investigated in the ACCESS (evaluation of Acute Candesartan Cilexetil therapy in Stroke Survivors) Study 8, which was designed to assess the safety of mild blood-pressure reduction in the early treatment of stroke, and to provide an estimate of the number of patients required for a larger efficacy and outcome study. The trial aimed to recruit 500 patients who had experienced a stroke approximately 30 hours before randomization. Patients were randomized to receive placebo or candesartan at an initial dose of 4 mg, increasing to 8 mg or 16 mg if systolic Fig. 4. Cumulative event rate (mortality and vascular events) in the ACCESS Study 8. Reproduced from Schrader et al with permission of Lippincott, Williams & Wilkins. blood pressure exceeded 160 mmhg or diastolic blood pressure exceeded 100 mmhg; the aim of treatment was to achieve a 10 15% reduction in blood pressure within 24 hours. A 24-hour blood-pressure profile was obtained on day 7. If the mean daytime blood pressure at this time exceeded 135/85 mmhg, patients in the candesartan group had the dose increased or a further antihypertensive drug added, while patients originally assigned to placebo were treated with candesartan at doses titrated to achieve a clinic blood pressure below 140/90 mmhg. The primary endpoint included both death and disability, measured as the Barthel Index 18 of functional status 3 months after the 7-day placebo-treatment period. Secondary endpoints included cardiovascular and cerebrovascular complications. Blood pressures in the two treatment groups were similar at the onset of the study, during the 7-day placebo-controlled period, and throughout the subsequent 12 months of follow-up. Of the 166 patients originally randomized to placebo, 164 required candesartan treatment because of a hypertensive 24-hour blood-pressure profile on day 7, and continued on this treatment for the remainder of the study. There were no significant differences in Barthel Index between the two groups at 3 or 12 months. However, the cumulative incidence of 12-month mortality and vascular endpoints was significantly reduced in the candesartan group, compared with the placebo group (Fig. 4). Cumulative 12-month mortality was 2.9% in the candesartan group, compared with 7.2% in the placebo group, and the corresponding vascular event rates were 9.8% and 18.7%, respectively (odds ratio 0.475; 95% CI: , P = ). As a result of this difference in event rates between the two groups, the trial was stopped prematurely when 342 patients had been randomized. Prevention of diabetes mellitus in hypertension and heart failure Recent large controlled studies have shown that AT 1 -receptor blockers significantly reduce the risk of developing diabetes mellitus. In hypertensive patients, the Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study, the Study of Cognition and Prognosis in the Elderly (SCOPE) with candesartan, and

4 H40 P. Trenkwalder the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Study showed reductions of 25%, 20% and 23%, respectively 3,9,19. Similarly, in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme, treatment with candesartan reduced the incidence of new-onset diabetes in patients with heart failure by 22% 20. Reduction of cardiovascular morbidity and mortality in hypertension Three large trials, the LIFE Study with losartan 3, the SCOPE study with candesartan 9, and most recently the VALUE study with valsartan 19 have investigated the impact of antihypertensive therapy with AT 1 -receptor blockers on cardiovascular mortality and morbidity. The LIFE Study involved 9193 hypertensive patients (aged years) with LVH, who received losartan mg or atenolol mg, for a mean of 4.8 years. Hydrochlorothiazide, mg, and other antihypertensive agents (other than ACE inhibitors, AT 1 -receptor blockers or b-blockers) could be added if required. Compared with atenolol, treatment with losartan was associated with a significant decrease in the incidence of cardiovascular death, stroke or acute myocardial infarction from 27.9 per 1000 patient-years to 23.8 per 1000 patient-years (relative risk 0.87, 95% CI: , P = 0.021) 3.AT 1 -receptor blockade also produced a significantly (P<0.0001) greater reduction in LVH, assessed by electrocardiographic criteria. In the subgroup of patients with diabetes at baseline (n = 1195), losartan reduced the incidence of cardiovascular death, stroke or myocardial infarction by 24% (P = 0.031), compared with atenolol, and there were also significant reductions in cardiovascular mortality (37% reduction, P = 0.028) and all-cause mortality (39% reduction, P = 0.002) 21. The SCOPE Study involved 4937 elderly patients (aged years) with treated or untreated hypertension (systolic blood pressure mmhg, diastolic blood pressure mmhg, or both) and a Mini Mental State Examination (MMSE) score of at least Previous antihypertensive medication was standardized to hydrochlorothiazide, 12.5 mg once daily, which was maintained throughout the study. Patients were originally randomized to receive candesartan, 8 16 mg, or placebo. However, for ethical reasons 84% of patients in the placebo group received other antihypertensive medication on an open-label basis. Thus, the placebo group should actually be considered an active control group. The mean duration of follow-up was 3.7 years. During the course of the study, 25% of patients in the candesartan group received candesartan alone, 26% received candesartan plus low-dose hydrochlorothiazide (given already at baseline), and 49% received candesartan plus open-label add-on therapy. The corresponding figures in the control group were 16%, 18% and 66%, respectively. Mean blood pressure decreased from 166.0/90.3 mmhg to 145.2/79.9 mmhg Fig. 5. Incidence of total and non-fatal stroke in the SCOPE Study 9. in the candesartan group, and from 166.5/90.4 mmhg to 148.5/81.6 mmhg in the control group. The mean difference in blood-pressure reductions achieved in the two groups was 3.2/1.6 mmhg (P<0.001 for both groups) in favour of the candesartan group. The incidence of the primary endpoint (a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) was reduced by 10.9% (95% CI: 6.0% to +25.1%, P = 0.19) in the candesartan group, compared with the control group. The incidence of total and non-fatal stroke was reduced by 24% (P = 0.056) and 28% (P = 0.04), respectively, in candesartan-treated patients compared with the control group (Fig. 5). Thus, in the SCOPE Study, a relatively modest difference in blood pressure between the candesartan and control groups was associated with a significant reduction in nonfatal stroke, and a trend towards a reduction in major cardiovascular events. A recent post hoc analysis from the SCOPE Study has investigated the incidence of clinical events in the subset of patients in each group who did not receive add-on antihypertensive therapy (n = 2098) 22. In these patients, candesartan significantly reduced the incidence of a first major cardiovascular event by 32.1% (P = 0.013), compared with the control group (Fig. 6). Overall mortality was also significantly reduced, by 27% (P = 0.018), in the candesartan group. The mean difference in blood pressure between the candesartan Fig. 6. Incidence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke in patients in the SCOPE Study who were not receiving add-on open-label antihypertensive therapy. Reproduced from Lithell et al with permission of Lippincott, Williams & Wilkins.

5 Preventing the cardiovascular complications of hypertension H41 and control groups in this subset of patients was 4.6/2.6 mmhg. A further analysis has investigated the effect of candesartan in patients with isolated systolic hypertension (n = 1518) 23. In these patients, candesartan was associated with a significant decrease of 42.5% (P = 0.049) in the risk of fatal or non-fatal stroke, compared with the control group. The mean difference in blood pressure in these groups was approximately 2/1 mmhg. The SCOPE and LIFE Studies, together with the IDNT and RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) 5 studies in diabetic patients were subjected to meta-analysis by the Blood Pressure Lowering Treatment Trialists Collaboration 24. This analysis showed that, compared with control antihypertensive therapies, AT 1 -receptor blockers reduced the risk of major cardiovascular events by approximately 10%, and that of stroke or heart failure by approximately 15 20%. The VALUE study, however, did not find any difference in its primary endpoint, a composite of cardiac mortality and morbidity, between valsartan-based therapy and amlodipine-based therapy 19. A total of 15,245 hypertensive patients (mean age 67 years) with a high risk of cardiovascular disease were randomized to valsartan mg or amlodipine 5 10 mg once daily, for a mean follow-up of 4.2 years. Hydrochlorothiazide, and subsequently other antihypertensive agents, could be added in both groups as necessary. Although the incidence of the primary endpoint was similar in the two groups, myocardial infarctions were significantly less frequent in the amlodipine group, and there was also a trend for less stroke. This appeared to be linked to a greater reduction in blood pressure in the amlodipine group, especially during the first part of the study, and thus highlights the importance of strict blood-pressure control in high-risk individuals. The incidence of heart failure tended to be lower with valsartan. Conclusions There is now good evidence that in addition to reducing blood pressure AT 1 -receptor blockers exert protective effects on target organs such as the heart, kidney and brain. The SCOPE and LIFE studies have shown that AT 1 -receptor blockade can reduce the incidence of cardiovascular complications of hypertension, compared with control therapies. The VALUE study, however, did not find a benefit of valsartan-based therapy compared with amlodipine-based therapy, and the study reinforces the need for strict blood-pressure control in high-risk individuals. All three major hypertension trials with AT 1 -receptor blockers, and the CHARM Study programme, have shown a lower incidence of new diabetes in patients treated with an AT 1 -receptor blocker compared with control therapy. AT 1 -receptor blockers represent an attractive option as first-line therapy for hypertension. References 1. Gradman AH. AT 1 -receptor blockers: differences that matter. J Hum Hypertens 2002;16:S Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21: Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359: Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345: Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: Parving H H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20: Schrader J, Lüders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil therapy in Stroke Survivors. Stroke 2003;34: Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21: Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121: Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. AmJMed1983;75: Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. AmJMed2003;115: Caruso D, D Isanto F, Maglione B, et al. Candesartan vs hydrochlorothiazide improves diastolic function in mild-to-moderate essential hypertension. J Hypertens 2000;18(Suppl 2):S153. Abstract. 14. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118: Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. Br Med J 1991;302: Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997;11(Suppl 2):S Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997;19: Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14: Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363: Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362: Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;259: Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004;22:

6 H42 P. Trenkwalder 23. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44(6): Blood Pressure Lowering Treatment Trialists Collaboration. Effects of blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2 Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic

More information

Lowering blood pressure in 2003

Lowering blood pressure in 2003 UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor

More information

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Overview of the outcome trials in older patients with isolated systolic hypertension

Overview of the outcome trials in older patients with isolated systolic hypertension Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated

More information

Cerebral involvement in hypertensive cardiovascular disease

Cerebral involvement in hypertensive cardiovascular disease European Heart Journal Supplements (2003) 5 (Supplement F), F19 F25 Cerebral involvement in hypertensive cardiovascular disease Hypertension Unit, Hospital Clinic (IDIBAPS), University of Barcelona, Barcelona,

More information

Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*

Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension* The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with

More information

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs (2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal

More information

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy (2006) 20, 169 175 & 2006 Nature Publishing Group All rights reserved 0950-9240/06 $30.00 www.nature.com/jhh REVIEW The importance of early antihypertensive efficacy: the role of angiotensin II receptor

More information

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management

Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr

More information

Journal of Hypertension 2007, 25: Received 27 November 2006 Revised 11 January 2007 Accepted 22 January 2007

Journal of Hypertension 2007, 25: Received 27 November 2006 Revised 11 January 2007 Accepted 22 January 2007 Original article 951 Blood pressure-dependent and independent effects of agents that inhibit the renin angiotensin system Blood Pressure Lowering Treatment Trialists Collaboration M Objectives To evaluate

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel

More information

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension

More information

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan Josep Redon, Maria Jose Fabia Key words: angiotensin receptor blocker, blood pressure, hypertension, olmesartan,

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression

More information

Traitements associés chez l hypertendu: Statines, Aspirine

Traitements associés chez l hypertendu: Statines, Aspirine Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact

More information

KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease

KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease KDIGO Controversies Conference on Management of Patients with Diabetes and Chronic Kidney Disease February 5-8, 2015 Vancouver, Canada Kidney Disease: Improving Global Outcomes (KDIGO) is an international

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management

Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management Bum-Kee Hong Yongdong Severance Hospital Yonsei University College of Medicine Rationale for Multiple-Mechanism Therapy Inadequacy

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Prevalence of left ventricular hypertrophy in a hypertensive population

Prevalence of left ventricular hypertrophy in a hypertensive population European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.

More information

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Kenji Ueshima 1, Shinji Yasuno 1, Sachiko Tanaka 1, Akira Fujimoto 1, Toshio Ogihara 2, Takao

More information

Noor Naif Al-Hakami. Pharm-D candidate (KSU)

Noor Naif Al-Hakami. Pharm-D candidate (KSU) Hypertension In Hemodialysis Patients Treated With Atenolol Or Lisinopril: A Randomized Controlled Trial (Rajiv Agarwal, Arjun D. Sinha, Maria K. Pappas, Terri N. Abraham and Getachew G. Tegegne ) Noor

More information

Morning Hypertension: A Pitfall of Current Hypertensive Management

Morning Hypertension: A Pitfall of Current Hypertensive Management Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between

More information

Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?

Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section

More information

Hypertensive Diabetic Patients. Guidelines for Conduct and Their Difficulties

Hypertensive Diabetic Patients. Guidelines for Conduct and Their Difficulties Original Article Hypertensive Diabetic Patients. Guidelines for Conduct and Their Difficulties Weimar K. S. Barroso, Paulo César B. V. Jardim, Thiago S. V. Jardim, Cláudio T. S. Souza, Alessandro L. A.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Type 2 diabetes mellitus is a common disease with substantial

Type 2 diabetes mellitus is a common disease with substantial Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Sandeep Vijan, MD, MS, and Rodney A. Hayward, MD Clinical Guidelines

More information

Slide notes: This presentation highlights the issues involved in preventing hypertension. Slide notes are included for the majority of slides,

Slide notes: This presentation highlights the issues involved in preventing hypertension. Slide notes are included for the majority of slides, 3/23/2016 1 This presentation highlights the issues involved in preventing hypertension. Slide notes are included for the majority of slides, containing source materials and references. 2 The Framingham,

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division

More information

Hypertension Management in Diabetic Patients

Hypertension Management in Diabetic Patients Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension (2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

Remission and Regression of Diabetic Nephropathy

Remission and Regression of Diabetic Nephropathy 515 Review Remission and Regression of Diabetic Nephropathy Hirofumi MAKINO, Yoshio NAKAMURA, and Jun WADA Diabetic nephropathy has become the single largest cause of end-stage renal disease (ESRD) worldwide.

More information

Initial Treatment of Hypertension

Initial Treatment of Hypertension The new england journal of medicine clinical practice Initial Treatment of Hypertension Phyllis August, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem.

More information

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD

More information

Renal protection by inhibition of the renin-angiotensinaldosterone

Renal protection by inhibition of the renin-angiotensinaldosterone Renal protection by inhibition of the renin-angiotensinaldosterone system Tomas Berl Key words: angiotensinconverting enzyme inhibitor, angiotensin receptor blocker, combination therapy, direct renin inhibitor,

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

The Role of ACEI and ARBs in AF prevention

The Role of ACEI and ARBs in AF prevention The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and

More information

Is Heart Rate a Treatment Target?

Is Heart Rate a Treatment Target? Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate

More information

Management of Stage B Heart Failure

Management of Stage B Heart Failure KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression

More information

Antihypertensive Combinations

Antihypertensive Combinations This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations

More information

Jun Cheng, MD; Wen Zhang, MMed; Xiaohui Zhang, MMed; Fei Han, MD; Xiayu Li, MD; Xuelin He, MD; Qun Li, MMed; Jianghua Chen, MMed

Jun Cheng, MD; Wen Zhang, MMed; Xiaohui Zhang, MMed; Fei Han, MD; Xiayu Li, MD; Xuelin He, MD; Qun Li, MMed; Jianghua Chen, MMed Research Original Investigation Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients

More information

For personal use. Only reproduce with permission from The Lancet publishing Group. Summary

For personal use. Only reproduce with permission from The Lancet publishing Group. Summary Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Christopher

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

ANTI- HYPERTENSIVE AGENTS

ANTI- HYPERTENSIVE AGENTS CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is

More information

Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?

Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney International, Vol. 66, Supplement 92 (2004), pp. S2 S6 Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? DICK DE ZEEUW Department of Clinical Pharmacology,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

Irbesartan in Patients with Atrial Fibrillation

Irbesartan in Patients with Atrial Fibrillation T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article in Patients with Atrial Fibrillation The ACTIVE I Investigators* A bs tr ac t The members of the writing group (Salim Yusuf, M.B.,

More information

Hypertension Management Focus on new RAAS blocker. Disclosure

Hypertension Management Focus on new RAAS blocker. Disclosure Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay

More information

Management of hypertension in patients with diabetes: the place of angiotensin-ii receptor blockers

Management of hypertension in patients with diabetes: the place of angiotensin-ii receptor blockers REVIEW ARTICLE doi: 10.1111/j.1463-1326.2009.01052.x Management of hypertension in patients with diabetes: the place of angiotensin-ii receptor blockers Rigas Kalaitzidis and George Bakris Hypertensive

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

ACE inhibitors vs ARBs: Is one class better for heart failure?

ACE inhibitors vs ARBs: Is one class better for heart failure? HEART FAILURE UPDATE MARK E. DUNLAP, MD * Associate Professor of Medicine, Physiology, and Biophysics, Case Western Reserve University School of Medicine, and Louis B. Stokes Cleveland VA Medical Center,

More information

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Cardiorenal End Points in a Trial of for Type 2 Diabetes Hans-Henrik Parving, M.D., D.M.Sc., Barry M. Brenner, M.D., Ph.D., John J.V.

More information

TREATMENT AND COMPLICAtions

TREATMENT AND COMPLICAtions ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and

More information

Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation

Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation Systematic Review and Meta-Analysis Medicine Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation A meta-analysis and systematic review of randomized

More information

Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis

Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. X, pp. 1 XX Copyright 2010 Via Medica ISSN 1897 5593 Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients:

More information

The Author(s) BMC Geriatrics 2017, 17(Suppl 1):224 DOI /s

The Author(s) BMC Geriatrics 2017, 17(Suppl 1):224 DOI /s The Author(s) BMC Geriatrics 2017, 17(Suppl 1):224 DOI 10.1186/s12877-017-0575-4 SYSTEMATIC REVIEW Open Access Effectiveness and safety of beta blockers in the management of hypertension in older adults:

More information

h i g h b l o o d p r e s s u r e

h i g h b l o o d p r e s s u r e h i g h b l o o d p r e s s u r e where are we at? The recent literature has raised doubts about the role of ßblockers for lowering blood pressure and the New Zealand Guidelines Group is updating the Assessment

More information

Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy Program Summary

Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy Program Summary OBJECTIVE The intent of the Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy (ST) program is to encourage use of cost-effective generic products - ACEIs, ACEI

More information

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? Journal of Human Hypertension (1999) 13, 505 509 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Echocardiographic definition of left ventricular

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine

Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine 831 Original Article Hypertens Res Vol.3 (27) No.9 p.831-837 Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Diuretics: drugs of choice for the initial management of patients with hypertension

Diuretics: drugs of choice for the initial management of patients with hypertension Review CONTENTS How everything began: the pioneering trials Second generation trials Why were diuretics less efficacious in preventing coronary heart disease in older trials? Trials comparing new antihypertensive

More information

THE SOUTHERN AFRICAN HYPERTENSION GUIDELINE. Brian Rayner, Division of Hypertension, University of Cape Town

THE SOUTHERN AFRICAN HYPERTENSION GUIDELINE. Brian Rayner, Division of Hypertension, University of Cape Town THE SOUTHERN AFRICAN HYPERTENSION GUIDELINE Brian Rayner, Division of Hypertension, University of Cape Town Scope of Problem Deaths attributable to high blood pressure in males, South Africa 2000 7000

More information

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg

More information

Editorial The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines

Editorial The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines Editorial Editorial The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines Therapeutic Advances in Cardiovascular Disease (2008) 2(1) 5 12 DOI: 10.1177/ 1753944707087409

More information

ORIGINAL INVESTIGATION. High Blood Pressure and Diabetes Mellitus. mellitus and hypertension in the same patient is devastating to the cardiovascular

ORIGINAL INVESTIGATION. High Blood Pressure and Diabetes Mellitus. mellitus and hypertension in the same patient is devastating to the cardiovascular ORIGINAL INVESTIGATION High Blood Pressure and Diabetes Mellitus Are All Antihypertensive Drugs Created Equal? Ehud Grossman, MD; Franz H. Messerli, MD; Uri Goldbourt, PhD Objective: To analyze the available

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

SPRINT trial: quoi de neuf en hypertension? Approche pratique du patient cardiaque en médecine. générale

SPRINT trial: quoi de neuf en hypertension? Approche pratique du patient cardiaque en médecine. générale SPRINT trial: quoi de neuf en hypertension? Approche pratique du patient cardiaque en médecine 17 ème édition du Congrès de la Ligue Cardiologique Belge 21 mai 2016 générale Philippe van de Borne Service

More information

Combination of renin-angiotensinaldosterone. how to choose?

Combination of renin-angiotensinaldosterone. how to choose? Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants

More information

Unmet Need in Hypertension and Heart Failure

Unmet Need in Hypertension and Heart Failure Angioplasty Summit 2008: Novartis Symposium Unmet Need in Hypertension and Heart Failure -ASPIRE HIGHER: Are there still existing unmet needs? What we expect from new antihypertensive treatment Sang Hong

More information

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,

More information

Combination therapy in the treatment of arterial hypertension. Franco Veglio SIIIA. UNIVERSITA degli STUDI di TORINO

Combination therapy in the treatment of arterial hypertension. Franco Veglio SIIIA. UNIVERSITA degli STUDI di TORINO SIIIA UNIVERSITA degli STUDI di TORINO FACOLTA DI MEDICINA E CHIRURGIA DIPARTIMENTO DI MEDICINA ED ONCOLOGIA SPERIMENTALE SCU MEDICINA INTERNA CENTRO IPERTENSIONE ARTERIOSA AOU S.GIOVANNI BATTISTA TORINO

More information

AFRICA CARDIOVASCULAR JOURNAL OF AFRICA Vol 23, No 3, April 2012

AFRICA CARDIOVASCULAR JOURNAL OF AFRICA Vol 23, No 3, April 2012 AFRICA CARDIOVASCULAR JOURNAL OF AFRICA Vol 23, No 3, April 2012 147 Prevalence of residual left ventricular structural changes after one year of antihypertensive treatment in patients of African descent:

More information

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study http://www.kidney-international.org & 28 International Society of Nephrology original article Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study GL Bakris 1, RD

More information

Management of Cardiovascular Disease in Diabetes

Management of Cardiovascular Disease in Diabetes Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western

More information

Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009

Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL

More information

Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis

Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis Research Original Investigation A Systematic Review and Meta-analysis Connor A. Emdin, HBSc; Kazem Rahimi, DM, MSc; Bruce Neal, PhD; Thomas Callender, MBChB; Vlado Perkovic, PhD; Anushka Patel, PhD IMPORTANCE

More information

Therapeutic approaches to slowing the progression of diabetic nephropathy is less best?

Therapeutic approaches to slowing the progression of diabetic nephropathy is less best? www.drugsincontext.com The journal of interventions in clinical practice REVIEW Therapeutic approaches to slowing the progression of diabetic nephropathy is less best? FULL TEXT ARTICLE Eva Vivian, 1 Chelsea

More information

Published trials point to a detrimental relationship

Published trials point to a detrimental relationship ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease

More information

Talking about blood pressure

Talking about blood pressure Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight

More information

A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide

A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide Int Cardiovasc Res J.2012;6(3):79-83. icrj:1726 A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide Reza Jafarzadeh Esfehani

More information

Choice of anti-hypertensive agents in diabetic subjects

Choice of anti-hypertensive agents in diabetic subjects 485250DVR10510.1177/1479164113485250Diabetes & Vascular Disease ResearchPatel and Mehta 2013 Review Article Choice of anti-hypertensive agents in diabetic subjects Diabetes & Vascular Disease Research

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor Treatment in Diabetic Nephropathy GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor Treatment in Diabetic Nephropathy GUIDELINES ACE Inhibitor Treatment in Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All patients with Type 1 or Type 2 diabetes mellitus complicated

More information